

Pfizer, Inc
66 Hudson Blvd E
New York NY 10001



December 16, 2024

A Message to the Growth Hormone Disorders Community

There may be intermittent supply constraints for select presentations of GENOTROPIN (somatropin) through April 2025 based off of current demand trends

The availability of growth hormone products in the U.S. has gone through significant changes since late 2022, with supply challenges impacting access to many medicines that patients rely on. To address these treatment supply constraints, Pfizer scaled up GENOTROPIN production significantly—producing 3.5x the number of GENOTROPIN pens in 2023 compared to 2022—but challenges have persisted due to continued high, unpredictable demand and market disruptions. Additionally, two daily growth hormone medications will be commercially discontinued between December 2024 and 2026.

Pfizer remains committed to the GENOTROPIN community and aims to proactively help the community navigate supply challenges. Any recommendations that we are making is not to withdraw from the growth hormone market, but to acknowledge the reality of the market situation and be flexible to best meet patients' needs. To facilitate access to GENOTROPIN, healthcare providers may consider other products for appropriate pediatric growth hormone deficiency (pGHD) patients, which may meet patients' needs, such as:

- Pfizer's once-weekly NGENLA® (somatrogon) or;
- Select presentations of GENOTROPIN MiniQuick® for which there is available supply

For non-pGHD patients who have fewer treatment options, healthcare providers may consider GENOTROPIN for the treatment of Prader-Willi Syndrome, Small for gestational age, Turner Syndrome, and Idiopathic short stature.

The Pfizer Bridge Program will provide support to patients prescribed GENOTROPIN or NGENLA. We have staffed the Bridge Program appropriately to help guide you through potential changes and answer questions you may have. For questions about supply and/or the availability of GENOTROPIN, or about starting your patient on NGENLA, please contact the Pfizer Bridge Program at 1 (800) 645-1280 from 9 AM-7 PM EST, Monday-Friday.

While the growth hormone treatment landscape has been unstable, we believe your proactive partnership will ultimately be an important part of a solution for the growth hormone disorder community. We are committed to continuing to support people living with growth hormone disorders that are seeking treatment and will continue to provide updates on the supply situation.